Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RY_SW01 cell injection for systemic sclerosis
ChiCTR2500102410Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2025
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of 89zr-oxine-ry_sw01 in systemic sclerosis (SSc) (5 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Incidence of dose-limiting toxicity, Incidence of adverse events and 1 more. Started May 2025; status: recruiting.
02
Drugs
89zr-oxine-ry_sw01
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2500102410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102410.